Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Gains from Investment Securities (2020 - 2025)

Bolt Biotherapeutics' Gains from Investment Securities history spans 6 years, with the latest figure at $288000.0 for Q1 2025.

  • For Q1 2025, Gains from Investment Securities changed N/A year-over-year to $288000.0; the TTM value through Sep 2025 reached $218000.0, up 129.58%, while the annual FY2023 figure was $10.7 million, 23692.31% up from the prior year.
  • Gains from Investment Securities for Q1 2025 was $288000.0 at Bolt Biotherapeutics, up from -$70000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $10.7 million in Q4 2023 and bottomed at -$12.2 million in Q4 2021.
  • The 5-year median for Gains from Investment Securities is $70000.0 (2024), against an average of $1218.6.
  • The largest annual shift saw Gains from Investment Securities tumbled 213.94% in 2021 before it surged 1426.71% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at -$12.2 million in 2021, then soared by 93.38% to -$807000.0 in 2022, then soared by 1426.71% to $10.7 million in 2023, then tumbled by 100.65% to -$70000.0 in 2024, then soared by 511.43% to $288000.0 in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Gains from Investment Securities are $288000.0 (Q1 2025), -$70000.0 (Q4 2024), and $70000.0 (Q3 2024).